FDA Gives Guidance on Geriatric Information in Labeling
The guidance document offers information on the placement and content of geriatric information in labeling of drugs and biologics.
FDA published guidance on Sept. 15, 2020 that provides recommendations for the content and placement of geriatric information in labeling of prescription drugs. The guidance is meant to ensure consistent placement of this type of information in the correct sections and subsections in labeling so that it is clear and accessible to healthcare practitioners.
The draft guidance document replaces a withdrawn guidance, Content and Format for Geriatric Labeling (October 2001), and gives examples of geriatric use statements in labeling and examples of when FDA may permit applicants to omit or revise required information. In the document, the agency discusses labeling when a drug is approved for general use by adults, including geriatric patients; a drug is approved for geriatric-specific indications; and a drug is not approved for geriatric patient use.
Source: FDA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
